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Abstract.
BACKGROUND: Hsp70 plays important role in the development and progression of cancer. Previously we described the asso-
ciation between serum Hsp70 levels and mortality of colorectal cancer.
OBJECTIVE: In this new prospective study we aimed to confirm and extend our previous findings in a larger cohort of patients,
based on a longer follow-up period.
METHODS: Two hundred and thirty-two patients diagnosed with colorectal cancer were enrolled in the study. Baseline serum
Hsp70 level and classical biomarker levels were measured. Patients were treated according to stage of the tumor and follow-up
lasted for a median 46.4 months.
RESULTS: We found that serum Hsp70 concentrations increase significantly with stage of the disease (1.79; 2.23 and 3.21 ng/ml
in stage I+II, III and IV respectively, p = 0.012 and 0.002, Mann-Whitney test) and with other known biomarkers of the disease.
We managed to confirm our previous findings that high baseline serum Hsp70 level (> 1.64 ng/ml) predicted poor 5-year sur-
vival (risk of death HR: 1.94 CI: 1.294–2.909; univariate; HR: 2.418 CI: 1.373–4.258; multivariate Cox regression analysis) in
the whole patient population and also in subgroups of stage IV and stage III disease. The strongest association was observed in
women under age of 70 (HR: 8.12, CI: 2.02–35.84; p = 0.004; multivariate Cox regression). The power of this colorectal cancer
prognostic model could be amplified by combining Hsp70 levels and inflammatory markers. Patients with high Hsp70, CRP and
high baseline WBC or platelet count had 5-times higher risk of death (HR: 5.07 CI: 2.74–9.39, p < 0.0001; and HR: 4.98 CI:
3.08–8.06, p < 0.0001 respectively).
CONCLUSIONS: These results confirm and validate our previous findings that serum Hsp70 is a useful biomarker of colorectal
cancer.
Keywords: Hsp70, colorectal cancer, prognostic model, CRP, survival
1. Introduction1
Heat shock proteins (Hsp) are a family of evolution-2
ary conserved proteins. Hsps are molecular chaperones3
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with a wide array of functions, including protein fold- 4
ing, transport, and also the repair and degradation of 5
damaged proteins. Hsps have a regulatory role in pro- 6
grammed cell death and apoptosis [1]. A prominent 7
member of the family is Hsp70, probably the most ex- 8
tensively investigated heat shock protein. Hsp70 plays 9
a key role in carcinogenesis. It is overexpressed in most 10
human cancers to promote cancer cell survival, prolif- 11
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eration and to evade apoptosis and other forms of can-12
cer cell death [2]. In the absence of Hsp70, tumor cells13
become senescent, a state of irreversible growth arrest14
with specific cell morphology. Senescent cells are un-15
able to proliferate and are eventually eliminated by the16
innate immune system (in [3,4]). On the other hand,17
high levels of intracellular Hsp70-1 correlate with tu-18
mor burden, advanced stage and worse prognosis in19
non-small cell lung cancer [5]; breast, endometrial, and20
uterine cervical carcinoma [6]. In a study of 81 primary21
human colorectal tissues the expression of Hsp70 and22
Hsp110 highly correlated with advanced clinical stages23
and lymph node involvement [7]. Hsp70 expression24
was associated with poor prognosis, decreased over-25
all survival in patients suffering from rectal cancer and26
squamous cell lung cancer [8] and resistance to on-27
cotherapy in some cancer patient groups [9].28
Beyond its intracellular occurrence Hsp70 can also29
be found in the plasma membrane of many solid tu-30
mors, while this is not true for normal tissues [10,11].31
Membrane-bound Hsp70 is not only a biomarker in ag-32
gressive tumors, but can serve as a potential target of33
antitumor therapies [12]. Moreover it can be released34
from the cell (the mechanism of this process is still not35
exactly clarified) and appear in the circulation in the36
form of soluble Hsp70 (sHSP70), both in healthy in-37
dividuals [13,14] and in various pathologic conditions.38
Circulating Hsp70 has been extensively investigated39
in a multitude of physiologic (pregnancy, aging) and40
non-physiologic (hearth failure, diabetes, liver disease,41
asthma, obesity) conditions (reviewed in [2]), on the42
other hand, it has been studied to a lesser extent in ma-43
lignancies. According to Gehrmann and co-workers,44
Hsp70 serum levels were significantly increased in pa-45
tients with hepatocellular carcinoma (HCC) compared46
to healthy controls and subjects with chronic hepati-47
tis [15]. Another group found a significant correlation48
between sHsp70 and gross tumor volume in adeno-49
and squamous cell carcinoma of the lung [16]. Previ-50
ously we reported on strong association between serum51
Hsp70 levels and stage, as well as unfavourable prog-52
nosis of small cell lung cancer [17].53
In 2010 we published preliminary data on the corre-54
lation between elevated serum Hsp70 levels and high55
mortality in a cohort of early stage colorectal cancer56
patients [18]. The present investigation is a confirma-57
tory work, aimed to reproduce previous findings on a58
larger cohort of prospectively followed CRC patients,59
with a longer follow-up period. We intended to prove60
that high serum Hsp70 level is a poor prognostic factor61
and propose a powerful prognostic model combining62
Hsp70 with easily accessible traditional biomarkers.63
Table 1













Right colon 43 (18.5)
Colon transversum 16 (6.9)









Definitive or palliative surgery 210 (90.5)
No surgery 22 (9.5)
2. Methods 64
2.1. Patients, controls and sample collection 65
Two hundred and thirty two patients diagnosed with 66
colorectal cancer and 110 controls were involved in the 67
study between January 2011 and June 2013 in the on- 68
cology ward of 3rd Department of Internal Medicine, 69
Semmelweis University. After confirmation of inva- 70
sive colorectal cancer with any stage, patients were 71
consented consecutively and clinical data and blood 72
samples were collected before starting anticancer ther- 73
apy. Baseline demographic and clinical characteris- 74
tics of patients are summarized in Table 1. Mean age 75
of patients was 66.8 years, with a male/female ra- 76
tio of 138/94. After diagnosis and adequate surgery 77
patients were treated and followed by the oncology 78
ward according to the stage of their disease and 79
to the actual national and European [19] guidelines. 80
Patients with rectal cancer received radiochemother- 81
apy before definitive surgery from cT3 or N+ dis- 82
ease. Twenty-two patients who had unresectable and/or 83
metastatic disease received upfront primary systemic 84
treatment without definitive surgery. During a follow- 85
up period that lasted for maximum 5 years (median 86
46.42 months), progression free survival and overall 87
survival data were collected. 88
The control group consisted of 110 healthy individ- 89
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Fig. 1. Baseline serum Hsp70 level of healthy subjects (N = 110) and colorectal cancer patients according to stage of the disease. Differences
between groups were calculated with Mann-Whitney test. Significant differences are shown between stages (Stage I+II vs III+IV and Stage
I–III vs IV). Non significant difference was observed between controls and patients with advanced (Stage IV) disease (not shown in the figure).
Explanation for stages: Stage I: T1-2 N0; Stage II: T3-4b N0; Stage III (IIIa-b): any T N1-2; Stage IV: any T any N M1 (according to 7th edition
of TNM staging system).
who underwent screening colonoscopy in the preced-91
ing 2 months and were free of colorectal cancer or92
premalignant lesions and whose history was negative93
for colorectal cancer or other malignancies. The study94
was approved by the Medical Research Council Sci-95
entific and Research Committee. Serum samples were96
aliquoted and stored at −70 degrees of Celsius for97
Hsp70 analysis.98
2.2. Serum Hsp70 analysis99
Soluble Hsp70 level was measured by using R&D100
Systems (Minneapolis, MN, USA, Catalogue No.101
DYC1663E) enzyme-linked immunosorbent assay kit.102
Ninety-six-well microtitre plates were coated with103
mouse anti-human Hsp70 capture antibody (100 µl;104
2 µg/ml) in carbonate buffer (pH 9.5) overnight at 4◦C.105
Plates were washed with phosphate-buffered saline106
(PBS) containing 0.1% Tween 20 three times and107
nonspecific binding sites blocked by incubation with108
200 µl of PBS containing 0.5% gelatinec and Tween 20109
for 1 h at room temperature. After washing, 100 µl of110
the reference preparation (recombinant human Hsp70, 111
0–10 µg/ml) or samples (1:1) were added and the 112
plates were incubated for 2 h at room temperature. 113
Plates were subsequently washed and Hsp70 bind- 114
ing was determined using biotinylated rabbit anti- 115
human antibody (100 µl; 0.5 µg/ml) in PBS gela- 116
tine. After 1.5 h at room temperature, plates were 117
washed and incubated with streptavidin-horseradish- 118
peroxidase (1:200) in PBS gelatine for 20 min at room 119
temperature. Plates were washed and 100 µl of o- 120
phenylene-diamine (Sigma, St Louis, MO, USA) in 121
citrate buffer was added. The optical density was mea- 122
sured at λ = 490 nm (reference at λ = 620 nm). The 123
detection range of the assay was 0.05–10 ng/ml, the 124
intra/inter-assay variability < 10/< 16%, respectively. 125
2.3. Tumor marker and other prognostic biomarker 126
analysis 127
Determination of the additional laboratory parame- 128
ters including complete blood counts, clinical chem- 129
istry and tumor markers were performed by Roche In- 130
tegra 800 analyzer, by Cell-Dyn 3500 hematology an- 131
alyzer at the time of study entry of each patient. 132
2.4. Statistical analysis 133
For descriptive purposes data are given as mean 134
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Table 2
Correlation between serum Hsp70 level and the known biomarkers
of colorectal cancer. Spearman’s rank correlation test was used
Biomarker All patients Significance Stage IV Significance
correlated with r (p) r (p)
serum Hsp70
WBC 0.060 0.365 0.363 0.010
CRP 0.066 0.323 0.362 0.010
LDH 0.234 < 0.001 0.367 0.009
SAP 0.168 0.015 0.377 0.012
THR 0.069 0.224 0.267 0.073
CEA 0.186 0.005 0.347 0.012
CA 19-9 0.214 0.002 0.500 0.001
tile range (IQR) if data were not Gaussian distributed. 136
The differences between groups were evaluated with 137
the Mann-Whitney test. Correlations between the vari- 138
ables were expressed using the non-parametric Spear- 139
man’s correlation coefficients. The association of ser- 140
um protein levels on survival was analysed with Cox 141
regression. Survival was calculated according to the 142
Kaplan-Meier method. The curves were compared for 143
statistical significance using long-rank testing. Re- 144
ceiver operating characteristic (ROC) curve analysis 145
was used to determine the optimal cut-off value of 146
Hsp70. Cut-off value of other biomarkers and tumour 147
markers were selected according to the upper level of 148
normal range used by the local laboratory. All tests 149
were two-tailed, p values of < 0.05 were accepted as 150
statistically significant. 151
Statistical analysis was performed using the Graph- 152
Pad Prism v6.01 (GraphPad Software Inc, San Diego, 153
CA, USA, www.graphpad.com) and SPSS v22 (SPSS 154
Inc., Chicago, IL, USA) software. 155
3. Results156
3.1. Serum Hsp70 concentration in patients with157
colorectal cancer according to stage of the158
disease and in healthy subjects159
We studied whether baseline serum concentration of160
soluble Hsp70 is different between patients with CRC161
and controls (Fig. 1). Circulating Hsp70 level was in162
the same range in the whole patient population and163
controls (2.21 (SD: 2.36) versus 2.55 (SD: 2.66) ng/ml,164
NS). However, within colorectal cancer patients Hsp70165
levels increased along with the stage of the disease. In166
early stage CRC (Stage I and II) mean Hsp70 level was167
1.79 ng/ml (SD: 1.53), in stage III it was 2.23 (SD:168
1.93) and in metastatic, stage IV disease we measured169
3.21 ng/ml (SD: 3.87). The difference was statistically170
Fig. 2. Survival (Kaplan-Meier) of colorectal cancer patients ac-
cording to high (black curves) or low (grey curves) serum Hsp70
level. A: all patients (n = 232); B: patients with metastatic stage
IV disease (n = 49); C: patients with stage III disease (n = 73).
Log Rank overall comparison showed significant difference in sur-
vival between patients with high (> 1.64 ng/ml) versus low (6 1.64
ng/ml) baseline serum Hsp70 level: 10.66; p = 0.001; 6.84; p =
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Table 3
Univariate and multivariate Cox-regression analysis: Association between baseline clinical parameters and serum biomarker levels and colorectal
cancer patient’s 5 year survival
Univariate Cox regression HR Significance Multivariate Cox regression HR Significance
(95% CI) (p) (95% CI) (p)
Age at diagnosis (> 68 year) 2.118 (1.394–3.216) < 0.001 2.223 (1.231–4.014) 0.008
Gender (male versus female) 1.070 (0.712–1.608) 0.745 NA
TNM Stage (stage IV versus stage I–III) 6.615 (4.312–10.150) < 0.001 6.516 (3.689–11.510) < 0.001
Tumor grade (grade 2/3 versus grade 1) NA NA
Grade 2 1.638 (0.885–3.033) 0.116
Grade 3 2.038 (1.006–4.131) 0.048
Tumor localization (right versus left colon) 1.430 (0.930–2.201) 0.103 NA NA
Hsp70 (> 1.64 ng/ml) 1.940 (1.294–2.909) 0.001 2.418 (1.373–4.258) 0.002
WBC (> 10 800 /ul) 2.368 (1.477–3.796) < 0.001 2.123 (1.076–4.186) 0.030
CRP (> 5 mg/l) 2.569 (1.634–4.040) < 0.001 NA NA
LDH (> 248 U/l) 1.750 (1.146–2.671) 0.010 NA NA
SAP (> 120 U/l) 3.175 (1.993–5.040) < 0.001 NA NA
THR (> 300 /ul) 1.611 (1.078–2.407) 0.020 NA NA
CEA (> 4 ng/ml) 3.141 (2.093–4.714) < 0.001 NA NA
CA 19-9 (> 39 ng/ml) 4.077 (2.559–6.509) < 0.001 NA NA
The cut-off value for serum biomarkers were the upper limit of their normal range (shown in column (1)). Cut-off value of serum Hsp70 level (>
1.64 ng/ml) was calculated by ROC curve analysis. The same variables were included in multivariate analyses (column (4)) as in the univariate
analysis (column (2)), and the best adjusted set of significant variables were highlighted.
significant between early and advanced stage disease171
(stage I+II versus III+IV, p = 0.012) or between non172
metastatic and metastatic (stage I–III versus stage IV,173
p = 0.002) disease.174
Presence or absence of a primary tumor at sample175
collection (i.e. sample collection before or after op-176
eration) was not associated with altered serum Hsp70177
levels. Similarly, we did not find a significant differ-178
ence in Hsp70 levels between right (n = 59, HSP70179
= 2.03 ng/ml) and left-sided (n = 173, Hsp70 =180
2.27 ng/ml) colorectal tumors.181
3.2. Correlation of soluble Hsp70 level with other182
biomarkers183
Hsp70 levels showed significant but weak positive184
correlation with tumor markers and other biomarkers185
that are known prognostic factors of CRC. These cor-186
relations were more pronounced (however also weak)187
in metastatic disease. In this subgroup we found posi-188
tive association of Hsp70 level with LDH, SAP, CRP,189
baseline platelet and white blood cell count as well as190
CA19.9 and CEA (Table 2).191
3.3. The relationship of Hsp70 and other biomarkers 192
with survival 193
Using the ROC curve analysis the cut-off value of 194
Hsp70 was 1.64 ng/ml. Values 6 1.64 ng/ml were re- 195
garded to be favorable and values > 1.64 unfavorable 196
prognostic markers. According to the Kaplan-Meier 197
survival estimate it is clearly demonstrated that high 198
Hsp70 levels correlate with poor survival in the whole 199
patient population, as well as in the subgroups of stage 200
IV (metastatic) and stage III disease (Fig. 2; p values 201
are 0.001; 0.009 and 0.06 respectively). The risk of 202
death within 5 years was two-fold higher with high ini- 203
tial Hsp70 level, according to univariate (HR: 1.94 CI: 204
1.29–2.91) and multivariate (HR: 2.42 CI: 1.37–4.26) 205
Cox regression analysis. In addition to Hsp70 level 206
age, tumor stage, grade, high WBC and platelet count, 207
high CRP, LDH, SAP and tumor marker proved to be 208
predictive factors of 5-year survival (Table 3). With the 209
multiple Cox regression analysis age, Hsp70, tumor 210
stage and high baseline white blood cell count were in- 211
dependent factors of death in the entire patient popula- 212
tion. As in our pivotal publication [18] we observed the 213
strongest relationship in the subgroup of women un- 214
der the age of 70. Using the same set of variables be- 215
side advanced stage of the disease (HR: 6.6, CI: 2.08– 216
21.48; p = 0.001), high Hsp70 level (HR: 8.12, CI: 217
2.02–35.84; p = 0.004, white blood cell number (HR: 218
6.8, CI: 1.56–29.79; p = 0.011) and high baseline CRP 219
level (HR: 6.6, CI: 1.84–24.22; p = 0.011) proved 220
to be the strongest independent predictors of death by 221
multiple Cox regression analysis. 222
3.4. Combined prognostic model of survival 223
Next we determined whether our earlier model [20] 224
that proposed the aggregate prognostic effect of high 225
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Fig. 3. Survival (Kaplan-Meier) of colorectal cancer patients accord-
ing to high serum Hsp70 and high CRP levels (black curves) versus
all other patients (gray curves). A: all patients (n = 232; χ2: 36.025;
p < 0.0001)); B: patients with metastatic stage IV disease (n = 49;
χ2: 7.443; p = 0.006); C: patients with stage III disease (n = 73;
χ2: 12.181; p < 0.0001). Cut off value for Hsp70: 1.64 ng/ml, CRP:
5 mg/l.
CRP could be validated in this new cohort. We found 227
that the combined effect of Hsp70 and CRP levels are 228
additive and exceeds that of Hsp70 alone in the whole 229
patient population (χ2: 36.025; p < 0.0001) as well 230
as in the different subgroups (χ2: 7.443; p = 0.006; 231
5.536; p = 0.019 and 12.181; p < 0.0001 in stage IV, 232
stage I–III and stage III groups respectively) (Fig. 3). 233
The power of this double model could be improved 234
by adding other inflammatory parameters like WBC or 235
platelet count. In the triple model patients with high 236
Hsp70, CRP and either high baseline WBC or platelet 237
count had a 5-times higher risk of death (HR: 5.07, CI: 238
2.74–9.39, p < 0.0001; and HR: 4.98, CI: 3.08–8.06, 239
p < 0.0001 respectively; χ2: 33.166; p < 0.0001 and 240
52.528; p < 0.0001 respectively). 241
4. Discussion242
In this prospective follow-up study we confirmed243
that baseline serum Hsp70 levels correlate with the244
stage of the disease and with many well established245
biomarkers of CRC. The most important result of the246
present study is the validation of the original observa-247
tions that Hsp70 is an independent, potent prognostic248
factor in colorectal cancer [18]. The risk of death with249
high serum Hsp70 level was very similar to what we250
described in the pivotal study. Also the highest risk was251
observed in women under 70 years of age, similarly252
to our earlier results. With the combination of two or253
three independent inflammatory/immune related prog-254
nostic factors (Hsp70, CRP and WBC or platelet count)255
we could establish a more potent prognostic model,256
supporting our previous results too. We believe that257
these results are strongly valid, based on concordant re-258
production in an independent patient cohort, therefore259
the possibility of fals conclusion is very low.260
In 1993 Ciocca and co-workers found highly ele-261
vated Hsp70 expression in breast cancer. They also262
observed that in cases without regional metastases at263
the time of diagnoses, 70% of patients with low lev-264
els of Hsp70 expression survived for 5 years, compar-265
ing with 30% survival of patients with high levels of266
Hsp70 [21]. This was the first implication of Hsp70 as267
a prognostic marker in cancer. In the following more268
than two decades extensive research was done in the269
field, and in addition to intracellular Hsp70, extracellu-270
lar (circulating) Hsp70 is also emerging as a biomarker271
of potential prognostic value in different types of can- 272
cer. 273
Our recent results are in line with our previous ob- 274
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nificantly correlate with poor outcome and predict a 276
shorter than expected overall survival. 277
Hsp70 is a versatile protein, crucial in maintain- 278
ing cellular integrity and homeostasis. Cancer cells 279
heavily depend on Hsp70 overexpression, since it pro- 280
tects them from exogenous (chemotherapy, irradia- 281
tion, hypoxia) and endogenous (oncogene accumula- 282
tion) stress. Oncogene accumulation engages senes- 283
cence (OIS = oncogene induced senescence) however, 284
cancer cells can bypass through the up-regulation of 285
Hsp70 [23]. Membrane-bound and extracellular Hsp70 286
is known to interact with the innate and adaptive im- 287
mune system, although this interaction is paradoxical 288
and not fully understood yet. On one hand, Hsp70 can 289
elicit an anti-tumor immune response, mainly by pre- 290
senting antigenic peptides to APCs, which in turn ac- 291
tivate cytotoxic T lymphocytes [24–27]. Natural killer 292
(NK) cells were found to kill mHsp70-positive tumor 293
cells after activation with a naturally occurring Hsp70 294
peptide (TKD) plus low dose IL-2 (TKD/IL-2). In their 295
ongoing proof-of-concept study Multhoff and her team 296
examine whether adjuvant treatment of NSCLC pa- 297
tients after platinum-based radiochemotherapy (RCTx) 298
with TKD/IL-2 activated, autologous NK cells is clin- 299
ically effective [11]. On the other hand there are data 300
supporting that Hsp70 can also play a role in sup- 301
pressing immune-mediated tumor-killing. Jaattela and 302
Wissing found that Hsp70 can protect cells from303
monocyte cytotoxicity [28], moreover; another group304
reported that membrane bound Hsp70, located in305
exosomes, can activate myeloid-derived suppressor306
cells, thereby counter-regulating anti-tumor immune307
responses [29].308
Knowing it’s multitude of housekeeping functions309
in cancer cells, it is no wonder Hsp70 is an important310
target of anti-cancer drug development [30,31]. More311
than a dozen Hsp70 inhibitors have been reported,312
some of these molecules reaching early phase clini-313
cal trials. Of note is 15-deoxyspergualin, ver-155008,314
PES and others ([32], review in [33]). Even though the315
primary target of these agents is intracellular Hsp70,316
high concentrations of circulating Hsp70 could influ-317
ence their efficacy and probably would have to be taken318
into account, in a future clinical scenario.319
The era of immuno-oncology is on the doorstep,320
with novel drugs (antibodies) targeting the immune321
system to enhance anti-tumor immunity, mainly by322
inhibiting cancer immune tolerance [34]. Knowing323
Hsp70’s interplay with the immune system it is an in-324
teresting question whether the concentration of serum325
Hsp70 influences the efficacy of immune-oncology326
treatments (i.e. PD-1 inhibitors); data are lacking in327
this field yet. On the other hand it is also a question,328
whether high circulating Hsp70 could influence pre-329
existing tumor-specific immune response. According330
to our present results it should be a negative effect,331
shifting the immune response toward immune toler-332
ance.333
Colo-rectal cancer is the second leading cause of334
cancer mortality worldwide, in 2017 more than 50000335
patients are estimated to die of the disease just in336
the US [35]. Apart from disease stage at diagno-337
sis, there are other prognostic factors that influence338
mortality in early CRC. Standard prognostic factors339
are grade of cancer, presence or absence of lym-340
phatic/venous/perineural invasion and the involvement341
of resection margins. High serum concentrations of342
CEA, and to a lesser extent CA19-9, indicate a negative343
prognosis. Bowel obstruction and perforation are clin-344
ical traits associated with poor prognosis [36]. From345
an array of molecular markers some have established346
prognostic value (18q deletion – negative for progno-347
sis; microsatellite instability/mismatch repair – posi-348
tive for prognosis), others are still under investigation349
(TP53, bcl-2 expression, TGF-alpha etc.) [37]. Recent350
research is focusing on the immune status and immune351
environment of colorectal cancer. According to Gal-352
lon and co-workers it seems that immunoscore, that353
reflects the amount of memory and cytotoxic T cells 354
in the tumor and tumor microenvironment is a strong 355
prognostic factor of survival [38]. 356
In summary, according to our recent and former very 357
concordant results, we propose that circulating Hsp70 358
levels could be considered in the staging and risk as- 359
sessment of colorectal cancer, either alone or in combi- 360
nation with CRP, platelet or WBC levels. Moreover, as 361
Hsp70 can modulate antitumor immunity, it is possible 362
that these findings will have relevance in the develop- 363
ment of new immunooncology therapy modalities. Re- 364
producibility of results hold considerable value in the 365
era of many unreproducible observations. 366
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